Forest Cuts A New Path But Remains Rooted In Primary Care
Forest’s new CEO outlined “Project Rejuvenate,” a strategy to recharge the drug marketer, Dec. 2. The program involves headcount and cost reductions and the sale of $1 billion in debt to fund share repurchases and bolt-on acquisitions. But the plan doesn’t call for a change in strategic direction since Saunders intends to strengthen Forest’s commitment to primary care.
Learn what's happening at the US FDA. On the go.
More from Marketing & Advertising
- • By
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
- • By
AbbVie’s migraine ad overstates the drug’s benefit, a problem that is amplified by using a celebrity, the agency says.
- • By
The lung cancer drug Krazati from Bristol Myers Squibb’s Mirati Therapeutics drew an FDA ad/promo untitled letter, highlighting the agency's trend of pursuing false or misleading efficacy claims, particularly when data comes from outside approved labeling.
- • By
The UK and EU pharma industry associations have defended their respective codes of practice despite alarming study results. Meanwhile, a consultation on proposals to revise the UK code received over 3,500 comments.
More from Compliance
HTA Regulation: EU Publishes Guidance On Validity Of Clinical Studies For Joint Clinical Assessments
• ByJoint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
- • By
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
- • By
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.
